Phase I clinical study evaluates safety and pharmacokinetics of ExeVir’s COVID-19 neutralizing antibody

By | August 19, 2021
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.